Nilotinib Stada

Nilotinib, the active ingredient in Nilotinib Stada, is a selective tyrosine kinase inhibitor presented as a tablet for oral use. It is indicated for the treatment of chronic myeloid leukemia and Philadelphia chromosome‑positive acute lymphoblastic leukemia in adult patients, targeting the BCR‑ABL fusion protein to inhibit leukemic cell proliferation.

GNH USA supplies Nilotinib Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide, with a focus on quality assurance and regulatory compliance.

Nilotinib is a targeted therapy that inhibits the BCR‑ABL tyrosine kinase pathway in certain leukemias.

- Chronic Myeloid Leukemia (CML): reduces disease progression and improves overall survival. - Philadelphia chromosome‑positive Acute Lymphoblastic Leukemia (Ph+ ALL): induces remission and prolongs survival. - Imatinib‑resistant CML: provides an alternative option for patients who have failed or are intolerant to first‑line therapy.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: loose stools that may be transient. - Rash: skin erythema or pruritus. - Fatigue: generalized tiredness.

Serious or Rare Side Effects: - QT prolongation: may lead to cardiac arrhythmias. - Pancreatitis: inflammation of the pancreas with abdominal pain. - Severe hepatic injury: marked elevation of liver enzymes or hepatitis. - Severe neutropenia: significant reduction in neutrophil count increasing infection risk.

Nilotinib requires careful monitoring and patient counseling. - Cardiac monitoring: obtain baseline ECG and repeat periodically due to QT risk. - Hepatic function: check liver enzymes before and during therapy. - Pancreatic enzymes: monitor amylase and lipase regularly. - Drug interactions: avoid concomitant strong CYP3A4 inhibitors and QT‑prolonging agents. - Pregnancy and lactation: contraindicated or unknown; advise effective contraception. - Store below 25°C: keep in the original pack, protect from moisture.

Nilotinib may interact with several medicines that affect its metabolism or cardiac safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase Nilotinib exposure. - QT‑prolonging drugs (e.g., quinidine, sotalol): additive risk of arrhythmia. - Other BCR‑ABL inhibitors: combined use can amplify toxicity.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., diltiazem, verapamil): may require dose adjustment. - CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce efficacy. - Acid‑reducing agents (e.g., omeprazole): may lower absorption and exposure.